The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease |
| Therapuetic Areas: | Nephrology / Urology |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 1/27/2019 |
| Start Date: | June 2019 |
| End Date: | April 2020 |
| Contact: | Michelle Chang |
| Email: | michelle.chang@nyumc.org |
| Phone: | 212 263 7439 |
The purpose of this study is to determine if multiple doses of vancomycin over the course of
3 months will perturb the intestinal flora (microbiome) and result in reduced serum
concentration of the uremic toxin indoxyl sulfate and p-cresyl sulfate. The design of the
study will permit investigators to assess the variability of serum uremic retention solute
concentrations with and without antibiotic over a three-month period.
3 months will perturb the intestinal flora (microbiome) and result in reduced serum
concentration of the uremic toxin indoxyl sulfate and p-cresyl sulfate. The design of the
study will permit investigators to assess the variability of serum uremic retention solute
concentrations with and without antibiotic over a three-month period.
Inclusion Criteria:
- Patients with stable chronic kidney disease on hemodialysis with a fistula or an AV
graft.
Exclusion Criteria:
- Antibiotics received within the last 3 months;
- recent diarrhea
- known allergy to vancomycin
- history of C. difficile infection
- elevation of white blood cell count or fever within one week of enrollment.
We found this trial at
1
site
550 1st Ave
New York, New York 10016
New York, New York 10016
(212) 263-7300
Principal Investigator: Jerome Lowenstain, MD
Phone: 212-263-7439
New York University School of Medicine NYU School of Medicine has a proud history that...
Click here to add this to my saved trials
